Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma arising from the perianal skin.
Biomarker and diagnostic research for anal margin squamous cell carcinoma has been reported in the published literature.
3 clinical trials registered. Interventions under study include other interventions, procedural interventions, drug therapy, and biologic therapy. Pipeline includes 1 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.
39 publications have been identified in PubMed for anal margin squamous cell carcinoma. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (21%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 11:10 PM UTC
44%
Disease patterns and progression | 8 | 21% |
Clinical study results | 7 | 18% |
Research summaries | 3 | 8% |
Testing and diagnosis research | 2 | 5% |
Laboratory research | 2 | 5% |
Burns J (2026). [PMID: 42096989](https://pubmed.ncbi.nlm.nih.gov/42096989/). *Surgery*. [Clinical Trial Publication]
Rastegar S (2026). [PMID: 41791835](https://pubmed.ncbi.nlm.nih.gov/41791835/). *HIV medicine*. [Epidemiology / Natural History]
Emile SH (2026). [PMID: 42102537](https://pubmed.ncbi.nlm.nih.gov/42102537/). *Surgery*. [Epidemiology / Natural History]
Rutland CD (2026). [PMID: 41725031](https://pubmed.ncbi.nlm.nih.gov/41725031/). *Appl Immunohistochem Mol Morphol*. [Diagnostic / Biomarker]
Takacs N (2026). [PMID: 41892185](https://pubmed.ncbi.nlm.nih.gov/41892185/). *Curr Oncol*. [Clinical Trial Publication]
Ang CH (2026). [PMID: 41625398](https://pubmed.ncbi.nlm.nih.gov/41625398/). *Archives of plastic surgery*. [Case Report / Case Series]
Ottoman O (2026). [PMID: 41923090](https://pubmed.ncbi.nlm.nih.gov/41923090/). *Infect Agent Cancer*. [Epidemiology / Natural History]
Irshad U (2026). [PMID: 32809549](https://pubmed.ncbi.nlm.nih.gov/32809549/). *Unknown Journal*. [Case Report / Case Series]
Gallina NC (2025). [PMID: 40706330](https://pubmed.ncbi.nlm.nih.gov/40706330/). *International journal of surgery case reports*. [Case Report / Case Series]
Burns L (2025). [PMID: 41428308](https://pubmed.ncbi.nlm.nih.gov/41428308/). *Irish journal of medical science*. [Case Report / Case Series]
AI-curated news mentioning anal margin squamous cell carcinoma
Updated Jun 3, 2026
A recent case study highlights an unusual presentation of anal squamous cell carcinoma, emphasizing the need for awareness and early diagnosis. This case contributes to the understanding of rare cancer manifestations.
The European Commission has approved Incyte's treatment for advanced squamous cell anal carcinoma (SCAC), marking the first systemic therapy available for adults with this condition. This approval represents a significant advancement in treatment options for patients suffering from advanced anal cancer.
EMA recommends extending the indication of Zynyz (retifanlimab) for treating advanced squamous cell carcinoma of the anal canal in adults. This marks a significant step in immunotherapy options for this patient population.